Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer

Future Oncol. 2016 Sep;12(17):1971-4. doi: 10.2217/fon-2016-0166. Epub 2016 Jun 17.

Abstract

The American Society of Clinical Oncology Genitourinary Cancers Symposium, Moscone West Building, San Francisco, CA, USA, 7-9 January 2016 The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held in San Francisco (CA, USA), from 7 to 9 January 2016, focused on 'patient-centric care: translating research to results'. Every year, this meeting is a must for anyone studying genitourinary tumors to keep abreast of the most recent innovations in this field, exchange views on behaviors customarily adopted in daily clinical practice and discuss future topics of scientific research. This two-part report highlights the key themes presented at the 2016 ASCO Genitourinary Cancers Symposium, with part 1 reporting the main novelties of kidney cancer and part 2 discussing the most relevant issues which have emerged for bladder and prostate tumors.

Keywords: biomarkers; genitourinary cancer; targeted therapy.

Publication types

  • Congress

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Transitional Cell / drug therapy*
  • Humans
  • Immunotherapy / methods
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / radiotherapy*
  • Radiation Dose Hypofractionation
  • San Francisco
  • Urinary Bladder Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents